FibroBiologics CSO buys $0.5M in stock via private placement

FibroBiologics, Inc. (Nasdaq: FBLG) announced the closing of a $0.5 million private placement on September 15, 2026, with Hamid Khoja, Ph.D., the company's Chief Scientific Officer, according to a press release.

Khoja purchased 298,508 shares of common stock along with warrants to purchase up to an additional 298,508 shares. Each share and accompanying warrant was sold at a combined price of $1.675, which reflects the Nasdaq Capital Market closing bid price of $1.55 per share on September 14, 2026, plus $0.125 per warrant.

The warrants carry an exercise price of $1.55 per share, are immediately exercisable, and expire five years from the date of issuance.

FibroBiologics said it intends to use the gross proceeds for general corporate purposes and working capital.

The securities were sold in a private placement under Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) of Regulation D, and have not been registered under the Securities Act or applicable state securities laws.

"I have spent years working with our passionate and dedicated team to build our fibroblast-based platform technology, and our discoveries every day continue to reinforce my confidence in the potential therapeutic capabilities of these cells," Khoja said in the statement.

FibroBiologics is a clinical-stage biotechnology company based in Houston focused on developing treatments for chronic diseases using fibroblast cells and fibroblast-derived materials.

You May Also Be Interested In

• Live Oak Acquisition Corp. VI prices $200M IPO on Nasdaq
• Limbach names Adam Prior as VP of investor relations
• Nauticus Robotics sets 1-for-6 reverse stock split for Sept. 25